Clinical Trial Update: Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial is evaluating naldemedine to prevent opioid-induced nausea and vomiting in cancer patients and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Naldemedine (Symproic) (naldemedine)

Snippet

Sponsor: International University of Health and Welfare | Conditions: Opioid-Induced Constipation (OIC) | Phase 4 | Status: RECRUITING